Collaborative Management of Patients With Estrogen Receptor–Positive Breast Cancer

November 6, 2016

Learning Objectives

  • Describe the mechanism of action of CDK inhibitors and how they differ from that of other forms of breast cancer treatments.
  • Explain why combining a CDK inhibitor with endocrine therapy may be beneficial in certain breast cancer subgroups.
  • Review the side-effect profile of CDK inhibitors, especially neutropenia, and how to manage toxicities while preserving dose delivery.
  • Determine when to adjust dosing of palbociclib for hematologic toxicities
Course summary
Available credit: 
  • 1.00 ACPE
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Attendance
  • 1.00 ANCC
Course opens: 
11/06/2016
Course expires: 
04/30/2017
Event starts: 
11/06/2016 - 10:45am
Event ends: 
11/06/2016 - 11:45am
Cost:
$0.00
Parent activity set: 
Rating: 
0
Gaylord National Hotel
National Harbor, MD
United States

Available Credit

  • 1.00 ACPE
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Attendance
  • 1.00 ANCC

Price

Cost:
$0.00
Please login or register to take this course.